MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome

Cancer Science

Volumn 99, Issue 4, 2008, Pages 720-725

  Tinguely, Marianne ^a   Jenni, B ^a,b   Knights, A ^a   Lopes, B ^a   Korol, D ^a,b,c   Rousson, V ^c   Curioni Fontecedro, A ^a   Cogliatti, S B ^d   Bittermann, A G ^b,e   Schmid, U ^d   Dommann Scherrer, C ^d   Maurer, R ^d   Renner, C ^a   Probst Hensch, N M ^a,b,c   Moch, H ^a   Knuth, A ^a   Zippelius, A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d NONE

^e TRIEMLI HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; GAGE ANTIGEN; KI 67 ANTIGEN; MAGE C1 ANTIGEN; MAGE C7 ANTIGEN; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMOSOME 13Q; CHROMOSOME 14; CHROMOSOME 16P; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 41349119162     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00738.x     Document Type: Article

References (26)

1. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502.
2. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
3. Reynolds C, Ratanatharathorn V, Adams P et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001; 27: 801-7.
4. Zeiser R, Finke J. Allogeneic haematopoietic cell transplantation for multiple myeloma: Reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. Eur J Cancer 2006; 42: 1601-11.
5. Lokhorst HM, Wu K, Verdonck LF et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4.
6. Simpson AJ, Caballero OL, Jungbluth A et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
7. Dhodapkar MV, Osman K, Teruya-Feldstein J et al. Expression of cancer/ testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3: 9.
8. Pellat-Deceunynck C, Mellerin MP, Labarriere N et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000; 30: 803-9.
9. van Baren N, Brasseur F, Godelaine D et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94: 1156-64.
10. van Rhee F, Szmania SM, Zhan F et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005; 105: 3939-44.
11. + T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 2005; 106: 4217-24.
12. Atanackovic D, Arfsten J, Cao Y et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109: 1103-12.
13. Jungbluth AA, Ely S, DiLiberto M et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005; 106: 167-74.
14. Tinguely M, Jenni B, Reineke T et al. Chromosomal translocations t(4; 14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities - a molecular epidemiologic study on tissue microarrays. Am J Surg Pathol 2007; 31: 690-6.
15. Cady FM, Muto DN, Ciabeterri G et al. Utility of interphase FISH panels for routine clinical cytogenetic evaluation of chronic lymphocytic leukemia and multiple myeloma. J Assoc Genet Technol 2004; 30: 77-81.
16. Martinez-Ramirez A, Cigudosa JC, Maestre L et al. Simultaneous detection of the immunophenotypic markers and genetic aberrations on routinely processed paraffin sections of lymphoma samples by means of the FICTION technique. Leukemia 2004; 18: 348-53.
17. Reineke T, Jenni B, Abdou MT et al. Ultrasonic decalcification offers new perspectives for rapid FISH, DNA, and RT-PCR analysis in bone marrow trephines. Am J Surg Pathol 2006; 30: 892-6.
18. Lee ET. Statistical Methods for Survival Data Analysis. Belmont, California: Woodsworth Inc, 1980.
19. Jaffe E, Harris NL, Stein H, Vardiman W. Pathology and Genetics of Tumours of Haematopathopoietic and Lymphoid Tissue. France: IARC Press, 2001.
20. + plasmacytic/B-cell infiltration. Int J Cancer 2007;120: 2411-7.
21. Chen YT, Gure AO, Tsang S et al. Identification of multiple cancer/ testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95: 6919-23.
22. Cho HJ, Caballero OL, Gnjatic S et al. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun 2006; 6: 12.
23. Vaughan HA, Svobodova S, Macgregor D et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 2004; 10: 8396-404.
24. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005; 6: 597-610.
25. Hoffmann MJ, Muller M, Engers R, Schulz WA. Epigenetic control of CTCFL/ BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 2006; 72: 1577-88.
26. Hogarth C, Itman C, Jans DA, Loveland KL. Regulated nucleocytoplasmic transport in spermatogenesis: A driver of cellular differentiation? Bioessays 2005; 27: 1011-25.